Effect of TB Treatment on Neutrophil-Derived Soluble Inflammatory Mediators in TB Patients with and without HIV Coinfection
- PMID: 37375484
- PMCID: PMC10303406
- DOI: 10.3390/pathogens12060794
Effect of TB Treatment on Neutrophil-Derived Soluble Inflammatory Mediators in TB Patients with and without HIV Coinfection
Abstract
The mycobacteriological analysis of sputum samples is the gold standard for tuberculosis diagnosis and treatment monitoring. However, sputum production can be challenging after the initiation of TB treatment. As a possible alternative, we therefore investigated the dynamics of neutrophil-derived soluble inflammatory mediators during TB treatment in relation to HIV ART status and the severity of lung impairment. Plasma samples of TB patients with (N = 47) and without HIV (N = 21) were analyzed at baseline, month 2, month 6 (end of TB treatment) and month 12. Plasma levels of MMP-1, MMP-8, MPO and S100A8 markedly decreased over the course of TB treatment and remained at similar levels thereafter. Post-TB treatment initiation, significantly elevated plasma levels of MMP-8 were detected in TB patients living with HIV, especially if they were not receiving ART treatment at baseline. Our data confirm that the plasma levels of neutrophil-based biomarkers can be used as candidate surrogate markers for TB treatment outcome and HIV-infection influenced MMP-8 and S100A8 levels. Future studies to validate our results and to understand the dynamics of neutrophils-based biomarkers post-TB treatment are needed.
Keywords: TB; TB treatment; multiplex; patients living with HIV.
Conflict of interest statement
The authors declare no conflict of interest.
Figures




References
-
- World Health Organization . Global Tuberculosis Report 2022. World Health Organization; Geneva, Switzerland: 2022.
-
- Pillay K., Lewis L., Rambaran S., Yende-Zuma N., Archary D., Gengiah S., Govender D., Hassan-Moosa R., Samsunder N., Abdool Karim S.S., et al. Plasma Biomarkers of Risk of Tuberculosis Recurrence in HIV Co-Infected Patients from South Africa. Front. Immunol. 2021;12:631094. doi: 10.3389/fimmu.2021.631094. - DOI - PMC - PubMed
-
- Sigal G.B., Segal M.R., Mathew A., Jarlsberg L., Wang M., Barbero S., Small N., Haynesworth K., Davis J.L., Weiner M., et al. Biomarkers of Tuberculosis Severity and Treatment Effect: A Directed Screen of 70 Host Markers in a Randomized Clinical Trial. EBioMedicine. 2017;25:112–121. doi: 10.1016/j.ebiom.2017.10.018. - DOI - PMC - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous